New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:55 EDTIDRA, IDRASummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Idera's (IDRA) toll-like receptor antagonist (IMO-8400) for Psoriasis on an Analyst/Industry conference call to be held on March 14 at 11 am.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
06:24 EDTIDRAPiper reiterates Overweight on Idera ahead of Saturday's data
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Idera Pharmaceuticals ahead of the company's Phase I/II data on IMO-8400 in Waldenstrom's lymphoma this Saturday, December 5 at the American Society of Hematology meeting. IMO-8400 could provide a safe combination in MyD-88 mutant B-cell lymphoma to extend Imbruvica duration of response, Tenthoff tells investors in a research note. He expects the data to serve as the primary near-term driver for Idera. The analyst has a $7 price target for the shares.
November 23, 2015
08:08 EDTIDRAIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 18, 2015
08:37 EDTIDRAIdera Pharmaceuticals appoints Joanna Horobin as Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use